QSAR treatment of meisoindigo derivatives as a potentbreast anticancer agent
Acta Chimica Asiana · 2019
DOI: 10.29303/aca.v2i2.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Chimica Asiana, 2019. Verfasst von Evie Kama Lestari und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
A quantitative structure-activity relationship (QSAR) analysis of meisoindigo derivatives as a breast anticancer has been carried out. This study aimed to obtain the best QSAR model in order to design new meisoindigo based compounds with best anticancer activity. The semiempirical PM3 method was used for descriptor calculation. The best QSAR model was built using multilinear regression (MLR) with enter method. It was found that there were 19 new meisoindigo derivativeswith better predictive a potent anticancer agent. The best compound was (E)-2-(1-((3-ethylisoxazol-5-yl)methyl)-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)acetamide with the value of IC505.31144 x10-15 (μM).
Zitieren
APA
Lestari, E. K., Ananto, A. D., Septiyana, M., & Hadisaputra, S. (2019). QSAR treatment of meisoindigo derivatives as a potentbreast anticancer agent. Acta Chimica Asiana. https://doi.org/10.29303/aca.v2i2.12
Vancouver
Lestari EK, Ananto AD, Septiyana M, Hadisaputra S. QSAR treatment of meisoindigo derivatives as a potentbreast anticancer agent. Acta Chimica Asiana. 2019. doi:10.29303/aca.v2i2.12
BibTeX
@article{Lestari2019,
author = {Lestari, Evie Kama and Ananto, Agus Dwi and Septiyana, Maulida and Hadisaputra, Saprizal},
title = {QSAR treatment of meisoindigo derivatives as a potentbreast anticancer agent},
journal = {Acta Chimica Asiana},
year = {2019},
doi = {10.29303/aca.v2i2.12}
}
EUVIMED